Clinical Trial Update: Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for TQB2303 in CD20-positive Diffuse Large B-cell Lymphoma (DLBCL) is provided, with status not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• TQB2303

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Diffuse Large B-cell Lymphoma | Phase 3 | Status: UNKNOWN